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ABSTRACT
Background. Anonymous primary care records are an import-
ant resource for observational studies. However, their external
validity is unknown in identifying the prevalence of decreased
kidney function and renal replacement therapy (RRT). We thus
compared the prevalence of decreased kidney function and
RRT in the Clinical Practice Research Datalink (CPRD) with
a nationally representative survey and national registry.
Methods. Among all people ≥25 years of age registered in the
CPRD for ≥1 year on 31 March 2014, we identiﬁed patients
with an estimated glomerular ﬁltration rate (eGFR) <60 mL/
min/1.73 m2, according to their most recent serum creatinine
in the past 5 years using the Chronic Kidney Disease Epidemi-
ology Collaboration equation and patients with recorded diag-
noses of RRT. Denominators were the entire population in each
age–sex band irrespective of creatinine measurement. The
prevalence of eGFR <60 mL/min/1.73 m2 was compared with
that in the Health Survey for England (HSE) 2009/2010 and
the prevalence of RRT was compared with that in the UK
Renal Registry (UKRR) 2014.
Results.We analysed 2 761 755 people in CPRD [mean age 53
(SD 17) years, men 49%], of whom 189 581 (6.86%) had an
eGFR <60 mL/min/1.73 m2 and 3293 (0.12%) were on RRT.
The prevalence of eGFR <60 mL/min/1.73 m2 in CPRD was
similar to that in the HSE and the prevalence of RRT was
close to that in the UKRR across all age groups in men and
women, although the small number of younger patients with
an eGFR <60 mL/min/1.73 m2 in the HSE might have ham-
pered precise comparison.
Conclusions.UK primary care data have good external validity
for the prevalence of decreased kidney function and RRT.
Keywords: chronic kidney disease, epidemiology, primary
care, renal replacement therapy, validity
BACKGROUND
Chronic kidney disease (CKD) is amajor public health problem
that increases in prevalence with age and is associated with in-
creased morbidity and mortality [1–3]. The number of people
with end-stage renal disease (ESRD) requiring renal replace-
ment therapy (RRT) has been increasing worldwide and is pre-
dicted to double by 2030 [4]. Appropriate identiﬁcation of CKD
is thus important for early intervention, including prevention of
both CKD progression and cardiovascular diseases [5]. At the
population level, accurate estimation of CKD prevalence is es-
sential to assess the burden of CKD in the community and to
evaluate the effectiveness of population approaches for CKD
[6]. However, potential methodological difﬁculties may make© The Author 201 . Published by Oxford University Press
on behalf of ERA-EDTA. This is an Open Access article distributed under the
terms of theCreativeCommonsAttribution License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction
in any medium, provided the original work is properly cited.
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it problematic to determine the community prevalence of CKD
[7, 8]. For example, people who have kidney function measured
routinely by serum creatinine may not represent the general
population and serum creatinine assays may not be uniformly
standardized.
Data derived from routine patient care, such as the anonym-
ous primary care records held in the UK Clinical Practice Re-
search Datalink (CPRD) [9], are an important resource for
observational studies [10]. Because CRPD broadly represents
the UK population in terms of demographics [11], it can be a
useful source to estimate a disease prevalence in the UK. How-
ever, using routine electronic records to investigate renal disease
is only possible if the general practitioners (GPs) appropriately
test, identify and record everyone in the population who has
kidney disease. Reliable measures of renal disease in electronic
health records would allow a more robust use of primary care
data to investigate renal disease epidemiology; for example, re-
searchers would be able to investigate the association between
kidney diseases and other comorbidities or medications re-
corded in primary care data. To date, a number of deﬁnitions
for diseases or speciﬁc conditions have been validated in the
CPRD at the individual or population level [12, 13]. However,
to our knowledge, there has been no external validation study
for the prevalence of decreased kidney function and RRT in the
CPRD. The best available methods to identify CKD and RRT in
CPRD are to use serum creatinine records measured by GPs
and recorded diagnoses of RRT in the CPRD, respectively, yet
the validity or appropriateness of these methods are unknown.
TheHealth Survey for England (HSE), a nationally represen-
tative survey of health condition, included measurement of kid-
ney function in 2009 and 2010 [14]. Every consenting
participant had kidney function measured, giving representa-
tive statistics for the prevalence of decreased kidney function
in the general population. Meanwhile, the UK Renal Registry
(UKRR), which records information regarding all people on
RRT in the UK, provides annual reports of the prevalence of
RRT [15]. Referring to these two nationally representative
sources of data, we aimed to evaluate the external validity of
the prevalence of decreased kidney function and RRT in the
CPRD.
MATERIALS AND METHODS
Details of the CPRD and study population
In the UK, the primary care system acts as a gatekeeper to
health care—patients need to be registered with a primary
care doctor to access National Health Service (NHS) non-
emergency care. Health care is free at the point of access. Pri-
mary care practices have used computerized electronic health
records since the early 1990s. There are only a limited number
of suppliers of GP electronic health record software. The CPRD
uses data from VISION software system (In Practice Systems,
London, UK) and has evolved as an observational data and
interventional research service provided by the NHS. Currently
>650 GP practices contribute data meeting quality control stan-
dards to the CPRD, covering and representing nearly 7% of the
UK population [11]. Previous studies have suggested that the
distribution of age, sex, ethnicity, practice location deprivation,
and other health indicators such as smoking and morbidities
are similar to that of external UK-based sources [11, 16–19].
The database includes patient demographics, coded diagnoses
and outpatient laboratory test results. The Secretary of State
waived informed consent for CPRD data because data are anon-
ymized and there is an overall beneﬁt for research. Ethical ap-
proval for this study was obtained from the Independent
Scientiﬁc Advisory Committee, which oversees research on
CPRD data (protocol no. 16_055), as well as the London School
of Hygiene and Tropical Medicine Ethics Committee (refer-
ence: 9196).
The study population was all people ≥25 years of age who
were alive and registered in the CPRD for at least 1 year on
31 March 2014. The choice of age 25 years as a lower limit
was made for the best comparability between the CPRD and
HSE or UKRR: the HSE and UKRR collected data of people
<25 years of age differently (the HSE grouped people 16–24
years of age, while the UKRR grouped people 18–24 years of
age). One-year registration was considered necessary for GPs
to record a history of RRT for newly registered patients or to
test their kidney function if they had a key CKD risk factor
such as diabetes [5].
Details of external data
For the prevalence of decreased kidney function, we com-
pared the data from the CPRD with those from the HSE 2009
and 2010 (combined) [14]. Brieﬂy, theHSE 2009/2010 included
a cross-sectional study of kidney disease among people selected
using a multistage stratiﬁed random probability sampling
method. Blood samples were taken from nearly 6000 consent-
ing participants, accounting for 77% for men and 73% for
women among all the HSE participants. Data were weighted
for non-response to reduce response bias. Creatinine was mea-
sured by an internationally standardized enzymatic method,
which is traceable to isotope dilution mass spectrometry
(IDMS) [20]. Estimated glomerular ﬁltration rate (eGFR) was
calculated from the serum creatinine value using the Modiﬁca-
tion of Diet in Renal Disease Study equation in the original HSE
report [14], whereas a post hoc analysis was conducted using the
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [21]. The prevalence of people with a sin-
gle eGFR <60 mL/min/1.73 m2 was reported according to age
(every 10 years) and sex.
For RRT prevalence, we referred to the data from the UKRR
2014 [15]. The UKRR 2014 collected data from all 71 renal cen-
tres in the UK. The prevalence of RRT in 2013 was estimated by
dividing the number of patients on RRT by the 2013 UK popu-
lation, according to age (every 10 years), sex and RRTmodality:
haemodialysis, peritoneal dialysis or kidney transplantation.
Deﬁnition of decreased kidney function and
RRT in the CPRD
We identiﬁed patients with an eGFR <60 mL/min/1.73 m2
according to their most recent single serum creatinine mea-
sured by a GP in the past 5 years (i.e. the period between 1
April 2009 and 31 March 2014) using the CKD-EPI equation
[22]. We used a single eGFR to deﬁne decreased kidney
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function in the main analysis because the HSE (reference data
in this study), as well as previous large epidemiological studies
[23, 24], have used this deﬁnition. For the main analysis, we
made the following assumptions: (i) all the UK laboratories re-
ported IDMS-traceable creatinine; (ii) people with a missing re-
cord of ethnicity in the CPRD had non-black ethnicity and (iii)
people without any creatinine measurement for the past 5 years
did not have decreased kidney function.
We identiﬁed patients on RRT based on the diagnoses re-
corded in the CPRD anytime from the date of their registration
to 31 March 2014. The list of diagnosis codes (Read codes) in-
dicative of RRTwas determined by using a recommended strat-
egy [25] and agreed upon among the authors (Supplementary
data, Table S1). In addition, in order to examine the validity of
diagnoses of different RRTmodality in CPRD, we classiﬁed pa-
tients with RRT into those with haemodialysis, peritoneal dia-
lysis or kidney transplantation. We used the most recent
recorded diagnosis, as this is the best available approach to es-
timate the prevalence of the current RRT modality in CPRD.
Data analysis
We calculated the prevalence [95% conﬁdence interval (CI)]
of eGFR <60 mL/min/1.73 m2 according to age (every 10 years)
and sex in the CPRD andHSE, respectively, using the CKD-EPI
equation. Denominators in the CPRD were the entire popula-
tion in each age–sex band irrespective of creatinine measure-
ment in the past 5 years. Patients ≥75 years of age were
grouped in the CPRD to be consistent with the HSE. We calcu-
lated the difference (95% CI) in the prevalence of eGFR <60
mL/min/1.73 m2 between the CPRD and HSE. We also re-
ported the proportion of patients with at least one creatinine
measurement for the past 5 years in the CPRD.
Similarly, we calculated the prevalence of RRT in the CPRD
and UKRR, respectively, and then the difference between the
CPRD and UKRR, in 10-year age bands by sex. We also re-
ported results by RRT modality.
All statistical analyses were conducted using Stata 14 soft-
ware (StataCorp, College Station, TX, USA).
Sensitivity analyses
We repeated our analyses using a number of alternative
eGFR deﬁnitions and restricted study populations in order to
determine the impact of the deﬁnition for decreased kidney
function that we used. We deﬁned decreased kidney function
as follows: (i) we assumed that all the UK laboratories reported
non-IDMS-traceable creatinine, and therefore multiplied the
recorded creatinine value by 0.95 to use the CKD-EPI equation
for IDMS-traceable creatinine [26]; (ii) we conducted a com-
plete case analysis for ethnicity (restricting the analysis to peo-
ple with recorded ethnicity in the CPRD); (iii) we used the
participants’ most recent creatinine in the past 2 years, instead
of 5 years; (iv) we restricted the region to England, by excluding
data from Scotland, Wales and Northern Ireland; (v) we add-
itionally required a measure of chronicity to deﬁne decreased
kidney function [27]: two or more eGFR results <60 mL/min/
1.73 m2 needed to be recorded consecutively ≥3 months apart
in the past 5 years; and (vi) we conducted a complete caseTa
bl
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analysis for creatinine by restricting the analysis to people with
at least one creatinine measurement in the past 5 years.
We also compared the prevalence of eGFR <45 mL/min/
1.73 m2 (calculated from the most recent creatinine in the
past 5 years) between the CPRD and HSE, which may be a
more robust indicator of decreased kidney function with prog-
nostic implications [28, 29].
RESULTS
From 685 GP practices, we identiﬁed 2 761 755 people [mean
age 53 (SD 17) years, men 49%] who were alive and registered
in the CPRD for ≥1 year on 31 March 2014. Their age–sex dis-
tribution was broadly similar to that of the UK Census 2013
(Supplementary data, Table S2). Of those identiﬁed, 189 581
patients (6.86%) had an eGFR <60 mL/min/1.73 m2 and 3293
patients (0.12%) were on RRT.
The prevalence of eGFR <60 mL/min/1.73 m2 increased
steeply with age (Table 1 and Figure 1). There was no evidence
that the prevalence of eGFR <60 mL/min/1.73 m2 in the CPRD
was different from that in theHSE across age groups, both inmen
and women, except for the group of men 25–34 years of age, in
which no one had an eGFR <60 mL/min/1.73 m2 in the HSE.
The proportion of people who had a recorded measurement of
creatinine increased with age, with 26% of men and 46% of
women 25–34 years of age with tests in the past 5 years, up to
92% (both men and women) among people 75 years of age.
The prevalence of RRT gradually increased according to age
(Table 2 and Figure 2). The difference between the CRPD and
the UKRR was small across all age groups, both in men and
women. Table 3 shows the subgroup analysis by RRT modality.
The prevalence of patients with haemodialysis in the CPRDwas
slightly lower than that in the UKRR across all age groups, while
the prevalence of those with peritoneal dialysis and kidney
transplantation in the CPRD were similar to or slightly higher
than those in the UKRR.
Table 4 shows the results of sensitivity analyses. By assuming
all creatinine results were non-IDMS traceable, the prevalence
of eGFR <60 mL/min/1.73 m2 in the CPRD decreased predom-
inantly among older people, and overall prevalence decreased
from 6.86 to 5.35%. Restricting to people with recorded ethni-
city in the CPRD, using a serum creatinine value in the past 2
years and restricting to English data produced similar results to
the main analysis. By deﬁning decreased kidney function in-
cluding a measure of chronicity, the prevalence decreased
slightly in each age group, and overall prevalence decreased
from 6.86 to 6.27%. Finally, in a complete case analysis (using
as the denominator only those with serum creatinine tests) the
prevalence of eGFR <60 mL/min/1.73 m2 increased substan-
tially compared to that in the main analysis.
The overall prevalence of eGFR <45 mL/min/1.73 m2 was
2.33% (64 425/2 761 755) in the CPRD. The number of people
with an eGFR <45 mL/min/1.73 m2 was small and CIs of the
prevalence estimates were large in the HSE (Table 5). The pro-
portion of people with an eGFR <45 mL/min/1.73 m2 in the age
group≥75 years in the CPRDwas signiﬁcantly higher than that
of the HSE, both in men and women.
DISCUSSION
In this study, we examined the external validity of the preva-
lence of decreased kidney function (based on serum creatinine
measured by GPs) and RRT (based on recorded diagnoses) in
the CPRD by comparing them with results from two nationally
representative sources (the HSE and UKRR). Across all ages for
men and women the prevalence of eGFR <60 mL/min/1.73 m2
in the CPRD was similar to that in the HSE, although the small
number of younger patients with an eGFR <60 mL/min/1.73
F IGURE 1 : Prevalence of eGFR <60 mL/min/1.73 m2 in the CPRD and HSE.
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m2 in the HSE might have hampered precise comparison. The
prevalence of RRT in the CPRD was broadly similar to that ob-
tained from the UKRR, although there were differences in the
RRT modality-speciﬁc prevalence between the CPRD and
UKRR.
Routinely collected primary care data can be a useful re-
source for epidemiological studies, particularly in the UK,
where >98% of citizens are registered with NHS GPs [11]. Al-
though the prevalence or incidence of various diseases in the
CPRD have good comparability with other UK-based data
sources [12, 13], the external validity of the prevalence of de-
creased kidney function and RRT has not been studied. Con-
cerns speciﬁc to kidney diseases include that GPs do not test
every registered patient’s kidney function, which could lead to
underestimation of the true prevalence of decreased kidney
function. In our study, the proportion of people with creatinine
measurement was small among young andmiddle-aged people,
especially men. However, using the entire practice population
as a denominator, the prevalence of eGFR <60 mL/min/1.73
m2 in the CPRD was close to that in the HSE across all age
groups, both in men and women. A possible explanation
would be that, in line with the current National Institute for
Health and Care Excellence (NICE) guidance for CKD [5],
GPs are efﬁciently testing kidney function for people with
CKD risk factors, including hypertension, diabetes, cardiovas-
cular diseases and hereditary kidney disease (e.g. autosomal
dominant polycystic kidney disease). In addition, the Quality
and Outcome Framework (QOF) incentivizes GPs to register
and manage patients with CKD [30]. Since the launch of the
QOF for CKD in 2006/7, the identiﬁcation and management
of patients with CKD have been improving in the UK [31], al-
though there are delays in coding patients with CKD in the sys-
tem [32]. In older age groups, very high proportions had
undergone testing of kidney function, and it is likely that
those not tested are healthier, with a lower risk of CKD.
In sensitivity analyses, we examined to what extent the
prevalence estimates for decreased kidney function changed
under different assumptions related to uncertainties in the
CPRD. First, the estimation changed considerably with the as-
sumption of whether the UK laboratories reported creatinines
traceable to IDMS or not. We expect that most of the UK la-
boratories reported IDMS-traceable creatinines during the
study period, yet if a few laboratories reported non-IDMS-
traceable creatinines, the true prevalence of eGFR <60 mL/
min/1.73 m2 in the CPRD would become lower than our esti-
mation in the main analysis. Standardization of serum creatin-
ine assays is thus important in studies regarding CKD
epidemiology. Second, the assumption of non-black ethnicity
for people with missing ethnicity data in the CPRD affected
the prevalence estimates only slightly. This is probably because
the proportion of people with black ethnicity is small in the UK,
at ∼3% [18]. Third, using creatinine records for the past 2 in-
stead of 5 years made little change to prevalence estimates for
decreased kidney function. This may relate to recommenda-
tions for regular testing in line with the QOF and the current
NICE guidance for CKD [5]. Fourth, in the CPRD the preva-
lence of eGFR <60 mL/min/1.73 m2 in England was similar
to that in the whole UK, ensuring comparability between theTa
bl
e
2.
P
re
va
le
n
ce
of
R
R
T
in
th
e
C
P
R
D
an
d
U
K
R
R
A
ge
gr
ou
p
(y
ea
rs
)
25
–3
4
35
–4
4
45
–5
4
55
–6
4
65
–7
4
≥
75
M
en P
re
va
le
nc
e
of
R
R
T
in
C
P
R
D
,%
(9
5%
C
I)
0.
05
(0
.0
4–
0.
06
)
0.
09
(0
.0
8–
0.
10
)
0.
14
(0
.1
2–
0.
15
)
0.
17
(0
.1
6–
0.
19
)
0.
22
(0
.2
0–
0.
24
)
0.
25
(0
.2
3–
0.
28
)
P
re
va
le
nc
e
of
R
R
T
in
U
K
R
R
,%
(9
5%
C
I)
0.
05
(0
.0
5–
0.
06
)
0.
10
(0
.1
0–
0.
10
)
0.
17
(0
.1
6–
0.
17
)
0.
22
(0
.2
1–
0.
22
)
0.
25
(0
.2
5–
0.
26
)
0.
29
(0
.2
8–
0.
29
)
D
iff
er
en
ce
(p
re
va
le
nc
e
in
C
P
R
D
−
U
K
R
R
),
%
(9
5%
C
I)
0
(−
0.
01
–0
.0
1)
−
0.
01
(−
0.
02
–0
)
−
0.
03
(−
0.
05
–−
0.
02
)
−
0.
05
(−
0.
06
–−
0.
03
)
−
0.
03
(−
0.
05
–−
0.
01
)
−
0.
03
(−
0.
06
–0
)
W
om
en
P
re
va
le
nc
e
of
R
R
T
in
C
P
R
D
,%
(9
5%
C
I)
0.
04
(0
.0
3–
0.
05
)
0.
07
(0
.0
6–
0.
08
)
0.
09
(0
.0
8–
0.
11
)
0.
13
(0
.1
1–
0.
14
)
0.
15
(0
.1
3–
0.
17
)
0.
12
(0
.1
0–
0.
13
)
P
re
va
le
nc
e
of
R
R
T
in
U
K
R
R
,%
(9
5%
C
I)
0.
04
(0
.0
3–
0.
04
)
0.
07
(0
.0
6–
0.
07
)
0.
11
(0
.1
0–
0.
11
)
0.
13
(0
.1
3–
0.
14
)
0.
15
(0
.1
5–
0.
16
)
0.
11
(0
.1
1–
0.
12
)
D
iff
er
en
ce
(p
re
va
le
nc
e
in
C
P
R
D
−
U
K
R
R
),
%
(9
5%
C
I)
0
(−
0.
01
–0
.0
1)
0
(−
0.
01
–0
.0
1)
−
0.
01
(−
0.
03
–0
)
−
0.
01
(−
0.
02
–0
.0
1)
0
(−
0.
02
–0
.0
2)
0
(−
0.
01
–0
.0
2)
O
R
IG
IN
A
L
A
R
T
IC
L
E
V a l i d i t y o f C K D & R R T p r e v a l e n c e i n U K p r i m a r y c a r e 5
HSE and CPRD in our study. Fifth, the prevalence estimates
slightly decreased by using the CKD criteria including chron-
icity. This may suggest that some patients with a single eGFR
<60 mL/min/1.73 m2 had transient kidney dysfunction, prob-
ably because serum creatinine was measured at the time of
acute illness when theymay have developed acute kidney injury.
Finally, the prevalence of decreased kidney function was likely
to be overestimated by restricting the denominator to only peo-
ple with creatinine measurement. This suggests that GPs select-
ively test people at high risk of CKD, especially among younger
people.
The prevalence of RRT was also similar between the CPRD
and UKRR across all age groups in men and women. Patients
receiving RRT are in frequent contact with kidney units, so
GPs do not provide comprehensive routine care for these indi-
viduals. However, patients on RRT remain registered with their
GPs and therefore we would anticipate that GPs update patient
records to reﬂect commencement of RRT. Our results suggest
that the estimated prevalence of RRT based on recorded diag-
noses in the CPRD was broadly valid when compared against
comprehensive UKRR. However, using the most recent diagno-
sis indicating RRT modality, the prevalence of haemodialysis
was underestimated in the CPRD, while those of peritoneal dia-
lysis and kidney transplantation were similar, or somewhat
overestimated, especially among older people. This may be be-
cause patients with peritoneal dialysis and kidney transplant-
ation are often healthier and have more regular contact with
their GPs compared with those on haemodialysis. In addition,
for patients with a change in their RRTmodality (e.g. from peri-
toneal dialysis to haemodialysis) there may be a delay in updat-
ing the modality in the GP record. Therefore, some patients
currently on haemodialysis might be misclassiﬁed into the
group of peritoneal dialysis or kidney transplantation because
their previous diagnoses (i.e. peritoneal dialysis or kidney trans-
plantation) are not yet updated. Another possibility is that
patients commencing haemodialysis died before this was re-
corded in the CPRD, given the high early mortality rates of
these patients [33].
There are several limitations to our study. First, this is a
cross-sectional study examining the validity of prevalence of de-
creased kidney function and RRT. Our results do not ensure
that UK primary care data are reliable for identifying the inci-
dence of CKD and RRT. Second, our comparison of data be-
tween the CPRD and HSE or UKRR was only at the
population rather than the individual level. Our analyses did
not allow us to calculate the sensitivity or speciﬁcity of RRT
diagnoses. In the absence of linked data, it is possible that
there was a similar extent of misclassiﬁcation between cases
and non-cases, resulting in an overall agreement of the preva-
lence estimates in the CPRD with those in the HSE and UKRR.
Third, the prevalence of decreased kidney function in the HSE
was the best available estimate, but not a perfect reference
standard. The survey did not include people who were tempor-
arily hospitalized for acute illness or were in residential care
[14]. In addition, people with poor health might be reluctant
to give a blood sample, and the existing adjustment for non-
response in the HSE may not have fully dealt with this bias.
This may explain the ﬁnding in our sensitivity analysis that
the proportion of people with an eGFR <45 mL/min/1.73 m2
in the oldest age group in the CPRD was signiﬁcantly higher
than that of the HSE. Blood sampling was conducted on only
one occasion in the HSE. Accordingly, we deﬁned decreased
kidney function in the CPRD using one serum creatinine meas-
urement in our main analysis. However, some patients might
have had their kidney function checked as a result of acute ill-
ness, and therefore their decreased kidney function might have
been transient. Previous research has shown that creatinine
ﬂuctuation can affect the CKDprevalence estimates in routinely
collected data [34], although the inﬂuence was not large in our
study. At ∼6000, the sample size in the HSE was not small, yet
F IGURE 2 : Prevalence of RRT in the CPRD and the UKRR
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Table 3. Prevalence of RRT by modality in the CPRD and UKRR
Age group (years)
25–34 35–44 45–54 55–64 65–74 ≥75
Clinical Practice Research Datalink
Denominator, N 472 625 509 884 579 490 463 212 393 519 343 025
Number of patients with haemodialysis, n (%) 39 (0.08) 84 (0.16) 144 (0.25) 202 (0.44) 257 (0.65) 378 (1.10)
Number of patients with peritoneal dialysis, n (%) 27 (0.06) 15 (0.03) 48 (0.08) 37 (0.08) 67 (0.17) 67 (0.20)
Number of patients with kidney transplantation, n (%) 141 (0.30) 299 (0.59) 480 (0.83) 455 (0.98) 399 (1.01) 154 (0.45)
UK Renal Registry
Denominator, N 8 676 837 8 463 148 9 030 893 7 297 460 6 030 602 5 101 203
Number of patients with haemodialysis, n (%) 887 (0.10) 1677 (0.20) 3513 (0.39) 4560 (0.62) 5939 (0.98) 7324 (1.44)
Number of patients with peritoneal dialysis, n (%) 180 (0.02) 321 (0.04) 585 (0.06) 740 (0.10) 918 (0.15) 830 (0.16)
Number of patients with kidney transplantation, n (%) 2836 (0.33) 5047 (0.60) 8361 (0.93) 7538 (1.03) 5224 (0.87) 1269 (0.25)
Table 4. Prevalence of eGFR <60 mL/min/1.73 m2 in the CPRD: results of main analysis and sensitivity analyses
Age group (years) Total
25–34 35–44 45–54 55–64 65–74 ≥75
Main analysis, % (numerator/denominator) 0.11
(497/472 625)
0.27
(1360/509 884)
0.83
(4800/579 490)
2.90
(13 455/463 212)
10.66
(41 949/393 519)
37.18
(127 520/343 025)
6.86
(189 581/2 761 755)
Sensitivity analyses, % (numerator/denominator)
(i) Assuming all creatinine results non-IDMS traceable 0.09
(429/472 625)
0.21
(1066/509 884)
0.56
(3246/579 490)
1.86
(8612/463 212)
7.45
(29 304/393 519)
30.66
(105 171/343 025)
5.35
(147 828/2 761 755)
(ii) Complete case analysis for ethnicity 0.11
(332/295 942)
0.27
(815/299 641)
0.93
(2710/292 837)
3.24
(7313/225 881)
11.26
(22 496/199 805)
38.25
(64 923/169 738)
6.64
(98 589/1 483 844)
(iii) Using creatinine records in past 2 years 0.09
(439/472 625)
0.24
(1202/509 884)
0.73
(4202/579 490)
2.59
(11 993/463 212)
9.93
(39 081/393 519)
35.08
(120 323/343 025)
6.42
(177 240/2 761 755)
(iv) Restricting region to England 0.11
(368/346 641)
0.26
(999/377 675)
0.85
(3596/423 030)
3.00
(9935/331 404)
10.71
(30 302/282 983)
37.22
(93 887/252 246)
6.91
(139 087/2 013 979)
(v) Using CKD criteria including chronicitya 0.07
(353/472 625)
0.19
(977/509 884)
0.56
(3234/579 490)
2.19
(10 156/463 212)
9.34
(36 770/393 519)
35.44
(121 564/343 025)
6.27
(173 054/2 761 755)
(vi) Complete case analysis for creatinine 0.29
(497/170 148)
0.57
(1360/238 786)
1.35
(4800/355 929)
3.93
(13 455/342 151)
12.50
(41 949/335 581)
40.38
(127 520/315 777)
10.78
(189 581/1 758 372)
aeGFR rate <60 mL/min/1.73 m2 twice consecutively for ≥3 months in the past 5 years.
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the relatively wide 95% CIs for the prevalence estimates in each
age–sex group hamperedmore precise comparisons. In particu-
lar, the number of patients with an eGFR <60 mL/min/1.73 m2
was small among younger age groups. We could not compare
the prevalence of more severe kidney dysfunction, because pa-
tients with an eGFR <30 mL/min/1.73 m2 were rare, even
among older people in the HSE [14]. Meanwhile, testing of al-
buminuria is known to be incomplete in UK primary care elec-
tronic health records [32], which prevented us from comparing
the prevalence of albuminuria, or CKD stages 1 and 2, between
the CPRD andHSE. Because albuminuria is an important prog-
nostic factor in people with and without low eGFR [35], the un-
known validity of albuminuria in UK primary care remains an
obstacle to the study of CKD using the CPRD. Finally, our ﬁnd-
ings may not be generalizable to other GP practices in the UK if
GP practices contributing to the CPRD were more likely to
measure kidney function and record the diagnoses of RRT.
Generalizability to primary care electronic health records in
other European countries is also uncertain, because the fre-
quency of practices such as blood testing, chronic disease mon-
itoring, recording of diagnoses, incentives and access to public
primary care clinics differ.
In the era of a rising global prevalence of ESRD [4], high-
quality epidemiological research on kidney diseases is becom-
ing more important. Routinely collected electronic health re-
cord data would play an important role for kidney research,
because most patients with CKD are diagnosed and managed
in primary care. Accurate identiﬁcation of CKD and RRT in
the CPRD would allow investigation of the association between
kidney diseases and other comorbidities or medications. It is
also possible to investigate equity of care (e.g. referral to ne-
phrologists), given that the database is less biased for ascertain-
ing advanced CKD than population surveys and disease
registries. In this study, we demonstrated that identifying the
prevalence of CKD and RRT is valid at the population level
in the CPRD. Although further validation of individual-level
data is needed, our ﬁndings support the use of UK primary
care data for research into kidney disease.
CONCLUSIONS
We examined the external validity of the prevalence of de-
creased kidney function and RRT in the CPRD. The prevalence
of eGFR <60 mL/min/1.73 m2 in the CPRD was similar to that
in a national sampling survey (HSE 2009/2010), and the preva-
lence of RRT in the CPRD was close to that obtained from a
national disease registry (UKRR 2014) across all age groups,
in both men and women. These ﬁndings suggest that UK pri-
mary care data can be used to identify the prevalence of de-
creased kidney function and RRT in future studies.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford-
journals.org.Ta
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